Rexall Sundown Arthri-Solution
FSIs promoting the glucosamine product appeared March 5 in national newspapers. The insert, featuring a photo of a senior couple dancing and a $2 coupon, states "unlike analgesics...Arthri-Solution works long-term to improve flexibility, comfort and range of motion." The 500 mg caplets come in 50-count and 110-count bottles that retail for $8.99 and $16.99; coupons are included in package inserts. Advertising for the product, which began shipping in January, remains under development. Arthri-Solution will be stocked in the pain reliever section of retail stores
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.
It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.
Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.